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Background: Most cystic fibrosis (CF) patients have exocrine pancreatic insufficiency (EPI) and need supplementation with pancreatic enzyme
replacement therapy (PERT). Liprotamase, a novel non-porcine PERT containing highly purified biotechnology-derived lipase, protease, and
amylase, has successfully undergone initial efficacy and safety testing.
Methods: In this international phase III parallel-group, randomized-withdrawal, double-blind placebo-controlled trial, CF patients with EPI 7 years
and older, including nutritionally and functionally compromised individuals, underwent baseline testing for coefficients of fat and nitrogen
absorption (CFA and CNA) and stool weight and frequency while off PERT. After an open-label treatment period with liprotamase, subjects were
randomized 1:1 to one liprotamase or placebo capsule taken with 3 meals and 2 snacks per day. The dose was fixed and increases were not
allowed. The same measurements were obtained again after treatment with double-blind study drug or placebo.
Results: 138 subjects were randomized. The adjusted least squares mean (LSM) difference between the treatment and placebo groups for change in
CFA was 15.1% (p=0.001) for the subgroup with baseline CFA b40%, 8.6% (p=0.006) for subjects with baseline CFA ≥40%, and 10.6%
(pb0.001) for the overall intent-to-treat population. Similar results were seen for change in CNA. Stool weight was significantly decreased
although not stool frequency. Liprotamase was well tolerated with no safety concerns identified.
Conclusions: In a CF patient population reflective of that encountered in clinical practice, this trial demonstrated that liprotamase at a fixed dose of
one capsule per meal or snack (5 capsules per day) was well tolerated and significantly increased fat absorption as measured by improvement in
CFA, significantly increased protein absorption as measured by improvement in CNA, and significantly decreased stool weight.
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the polymeric coating leading to variable absorption and
digestion along the length of the small intestine [4], viral
contamination [5], batch-to-batch variation and loss of enzyme
activity over time, and consequent instances of serious under-
and overdosing [2,6–12] led to a requirement for FDA-
approved PERTs to have tighter chemistry, manufacturing
and controls and to a search for an improved and non-porcine
PERT.
Liprotamase is a novel non-porcine PERT, containing a
proprietary biotechnology-derived formulation of cross-linked
crystalline lipase, crystalline protease, and amorphous amylase
that has been designed for purity (no viral contamination) and
precise dose standardization. The three enzymes were chosen
based upon their broad substrate specificity, resistance against
proteolysis, and stability at acid pH for reliable potency of
activity in the proximal small intestine [13–16]. Since the
stability in harsh environments is engineered into the individual
enzymes, polymeric coating is not required.
To date, PERT studies have been small in size, of short
duration, and conducted in selective patient populations [17].
Most PERT studies in which CFA is measured have included
“dose stabilization” or “normalization” periods during which
doses are adjusted based on malabsorption symptoms [17–20].
In some studies, “nonresponders” have been excluded based on
the requirement that the on-enzyme CFA must be ≥80% in
order for subjects to be eligible for randomization [17,20]. In
other studies, the dose selected was thought to maximize fat
absorption based on clinical titration [18,19].
The 726 Study Group intended to conduct this phase III trial
in a broad-based population of CF patients with PI documented
by low baseline CFA or fecal elastase who were in the United
States, Europe, South America, and other parts of the world.
The responder enrichment strategies outlined above were not
employed. An initial phase I study with liprotamase demon-
strated good safety and clinical activity in CF patients with EPI
[21], and a phase II dose-finding study of 3 different dosages
resulted in the selection of amidrange fixed dose at eachmeal and
snack for further study [22]. We report the efficacy and safety
results of a placebo-controlled trial of a fixed liprotamase dose of
one capsule (containing 32,500 United States Pharmacopeia
[USP] U crystallized cross-linked lipase, 25,000 USP U
crystallized protease, and 3750 USP U amorphous amylase)
with each meal and snack (total of 5 capsules per day), in a broad-
based population of pancreatic-insufficient CF patients.
2. Methods
This international phase III parallel-group, randomized-
withdrawal, double-blind, placebo-controlled trial was con-
ducted between May 2007 and June 2008 at 23 sites in the
United States and 11 sites outside the United States with
expertise in treating patients with CF (NCT #449878). The
study protocol and informed consent form were approved by the
institutional review board/independent ethics committee at each
site. All subjects or their legal representatives provided written
consent, and in the case of pediatric patients (b18 years of age),assent. Safety oversight was provided and standard stopping
rules were set in conjunction with a study-specific committee of
the US Cystic Fibrosis Foundation (CFF) Data Safety
Monitoring Board.
2.1. Study subjects and design
Males and females ≥7 years of age were eligible for the trial
if they had documented evidence of the diagnosis of CF (sweat
chloride N60 mmol/L or two CF-causing mutations), had EPI as
defined by a fecal elastase [1] ≤100 μg/g stool and CFA ≤80%
while off enzymes, were clinically stable, were able to
discontinue use of their current PERTs, and were able to
undergo the designated testing and inpatient stays. Under the
broad-based population study design, no exclusions were made
based on BMI, BMI percentile, weight loss, nutritional status,
malabsorption symptoms, or PERT dose stability at enrollment.
Subjects were excluded if there was a history of fibrosing
colonopathy, organ transplantation, significant bowel resection,
distal intestinal obstructive syndrome (DIOS) in the prior
6 months, or any acute or chronic diarrheal illness unrelated to
EPI. Subjects were also excluded for baseline elevation of liver
transaminases N5 times or bilirubin N1.5 times the upper limit
of normal, inability to discontinue enteral tube feedings during
the study, or known hypersensitivity to food additives.
The study was divided into five phases (Fig. 1), as follows:
(1) screening; (2) inpatient off-enzyme baseline phase; (3) open-
label outpatient treatment phase of 21 to 31 days during which
all subjects received a fixed dose of liprotamase; (4) inpatient
randomized double-blind treatment phase of 6 days; (5) second
open-label treatment phase of 1 week. Eligible subjects received
diet instructions at the screening visit and were admitted to an
inpatient facility within the next 4 weeks to begin the off-
enzyme baseline phase (phase 2). Each subject ate a high-fat
diet, starting 4 days prior to admission, and discontinued the
usual PERT 1 day prior to admission. The second day of the
wash-out off PERT was performed at the inpatient facility. After
baseline blood glucose determination, each subject underwent a
starch challenge test (SCT) following a breakfast meal limited
to white flour bread (50 g of carbohydrate), followed by serial
blood glucose measurements as previously described [22]. The
SCT was not performed on subjects receiving treatment with
either oral hypoglycemic agents or insulin. After the two PERT-
free days, each subject began a controlled 72-hour diet
consisting of 2 g of protein per kg per day and 100 g of fat
per day (or 38% of total calories per day for children unable to
consume 100 g of fat). Two 250-mg FD&C blue #2 marker
capsules were given at the beginning and end of the 72 h [21].
Stool was collected after passage of the first blue marker up to
and including the second blue marker for determination of CFA,
coefficient of nitrogen absorption (CNA), and stool weight and
frequency. The collected stool and laboratory serum samples
were shipped frozen to Mayo Clinical Laboratory Services
(Rochester, MN, USA) for analysis and measurement using
NMR spectroscopy [23].
At the completion of the stool collection, subjects were
discharged from the inpatient facility and were instructed to take
Fig. 1. The international phase III randomized withdrawal, double-blind, placebo-controlled trial of the efficacy and safety of liprotamase in cystic fibrosis (CF)
patients with exocrine pancreatic insufficiency (EPI). Trial design and subject disposition.
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and two snacks (5 capsules) daily. They were not allowed to
adjust this dose based upon symptoms or other considerations.
This open-label portion of the study (phase 3) was intended to
allow a short adjustment period to liprotamase prior to
randomized withdrawal. A CF-specific multivitamin enriched
with vitamins A, D, E, and K was provided to all US subjects.
Subjects outside the United States were encouraged to take fat-
soluble vitamins, but such vitamins were not supplied by the
trial sponsor. Subjects with confirmed pancreatic insufficiency
defined as a baseline CFA ≤80% continued in the open-label
liprotamase treatment phase (phase 3) and were eligible for
randomization to receive double-blind liprotamase or placebo in
the inpatient double-blind treatment phase (phase 4). At
randomization, subjects were stratified according to CFA b40%
versus CFA ≥40%. Subjects with baseline CFA N80% were not
eligible to be randomized. Subjects were also stratified according
to whether they were receiving daily acid suppression therapy at
baseline; subjects who were receiving daily acid suppression
therapy at baseline remained on their prescribed acid suppression
drugs and dosages throughout the study. Subjects underwent
safety evaluations weekly after beginning the study drug.
The inpatient double-blind treatment phase (phase 4) began
21 to 31 days after the start of open-label treatment for each
subject. At that time, subjects were randomized 1:1 either to
continue the treatment with liprotamase or to be switched from
liprotamase to placebo for a period limited to 6 days. Beginning
on day 2 of this randomized study phase, each subject was
readmitted to the inpatient facility for repetition of the
controlled diet with foods identical to those in the off-enzyme
baseline phase and again underwent testing for determination of
the same endpoints as in the off-enzyme baseline phase.
Upon discharge, subjects resumed outpatient open-label
treatment at the same dose (phase 5) for 1 additional week prior
to resuming their usual-care porcine enzyme therapy.
Study drug compliance was assessed throughout the trial
by means of pill counts and weekly review of mandatory
study drug and vitamin diaries. Safety evaluations were
performed throughout the trial, including medical history and
physical examinations, vital sign measurements, standardclinical laboratory testing, assessment of adverse events and
serious adverse events for severity and causality, and documen-
tation of concomitant medications, treatments, and procedures.
After completing the study, each subject returned approximately
2 weeks later for a follow-up safety evaluation.
2.2. Study drug and dosage
Liprotamase is a non-porcine PERT containing highly
purified biotechnology-derived enzymes (lipase, protease, and
amylase). The lipase and protease are crystallized, and the
crystallized lipase is cross-linked to increase shelf life and
stability in harsh conditions such as low pH and exposure to
proteolytic enzymes. The amylase is amorphous. Selected on
the basis of their broad substrate specificity and stability in the
pH of the gut and their similarity in activity to their human
counterparts, the enzymes do not require polymeric coating for
protection against acid hydrolysis or proteolysis. Each lot of the
individual drug substances is tested to ensure compliance to
specifications, including biologic purity and activity. The three
drug substances are blended together with pharmaceutical grade
excipients and dispensed into a size 2 gelatin capsule at a fixed
ratio of lipase:protease:amylase activities of 1.3:1:0.15. Each
liprotamase capsule used in the trial contained 32,500 USP U
lipase activity, 25,000 USP U protease activity, and 3750 USP
U amylase activity. The rationale for the dosing proportions has
been previously described [22]. The single-capsule fixed
liprotamase dosing represented the mid-range effective dose
identified in the phase II dose-finding study of liprotamase. The
placebo consisted of microcrystalline cellulose PH112 dis-
pensed into size 2 gelatin capsules that were identical to the
liprotamase capsules in appearance and weight. All subjects
were to take one capsule of liprotamase or placebo orally in the
middle of each of three meals and two snacks per day during the
treatment phases.
2.3. Study endpoints and statistical methods
The primary objective of the study was to determine the
efficacy of liprotamase for the treatment of fat malabsorption in
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determine the efficacy of liprotamase in these subjects for the
treatment of protein malabsorption and carbohydrate malabsorp-
tion and to evaluate the ability of liprotamase to decrease stool
weight and frequency. The safety objective was to evaluate the
safety and tolerability of liprotamase in the study population.
The primary efficacy endpoint was change in CFA between
the inpatient off-enzyme baseline phase (phase 2) and the
inpatient double-blind treatment phase (phase 4). Secondary
efficacy endpoints for similar comparison were change in CNA;
response to glucose with the SCT in non-diabetic subjects; and
changes in stool weight and frequency.
The primary efficacy analysis was prospectively defined to
compare the mean change in CFA for the subjects randomized
to liprotamase versus those randomized to placebo in the
subgroup with baseline CFA b40% based on the results of our
phase 2 study [22] An analysis of covariance (ANCOVA)
model with fixed effects for treatment group and acid-
suppressant (H-2 blockers, proton pump inhibitors) usage was
used to determine the least squares mean (LSM) difference
between the treatment groups for the adjusted change in CFA,
with corresponding 95% confidence interval (CI) values.
Supportive efficacy analyses for the overall population and
for the subgroup with baseline CFA ≥40% but ≤80% used the
same statistical model with the addition of baseline CFA
subgroup for the overall population. An initial test of 2-way
interactions was made; interactions significant at p≤0.10 were
to be retained in the ANCOVA model. The secondary endpoint
of change in CNAwas analyzed using the same approach as that
for CFA. Response to glucose was analyzed using a logistic
regression model with the same fixed effects as the other
analyses, and the relative risk (with associated 95% CI) of not
achieving this endpoint was estimated for the liprotamase group
versus the placebo group. Changes in stool weight and
frequency were analyzed using the ANCOVAmodels described
for change in CFA.
The intent-to-treat (ITT) population was defined as all
subjects randomized during the inpatient double-blind treatment
phase (phase 4) of the trial. The population for primary safety
analyses included all subjects who received at least one dose of
study drug and had at least one safety measurement.
The planned sample sizes assumed a treatment to placebo
ratio of 1:1, a type I error rate of 0.05, a two-sided test, and a
common standard deviation (SD) of 18%. In the overall
population, the target sample size of 144 evaluable subjects
allowed for the detection of an improvement of 15.56% in mean
change in CFA with at least 99% power, which corresponded to
an effect size of 0.86, consistent with approved therapies that
are considered as moderately effective.
Given a dropout rate of 10% in each baseline CFA subgroup,
46 subjects with baseline CFA b40% and 116 subjects with
baseline CFA≥40% but≤80% needed to be enrolled. Based on
an estimated 8% of the subjects having a baseline CFA N80%
[22], approximately 176 total subjects were to be enrolled into the
study.
Adverse events, changes in clinical laboratory parameters,
and vital signs were analyzed descriptively for each treatmentgroup. Shifts in key laboratory parameters were summarized by
treatment group from baseline to the end of the study.
Data management was performed by Quintiles (Livingston,
GA, USA), the data management system built with InForm
(validated for version 4.5). Study database analyses and reports
were conducted and reported using Access 2000, Crystal
Reports version 8, and/or SAS version 9.1 (Cary, NC).
3. Results
3.1. Study population
Between May 2007 and June 2008, a total of 200 subjects
were screened for study participation (Fig. 1). Of these, 35 did
not meet the eligibility criteria, and 2 additional subjects
withdrew prior to receiving any study drug; the remaining 163
subjects, constituting the trial safety population, commenced
treatment with the study drug during the open-label outpatient
treatment phase (phase 3). During the inpatient double-blind
treatment phase (phase 4), 138 subjects were randomized at 23
sites in the United States (n=68) and 11 sites outside the United
States (n=70: at 3 sites in Slovakia, 3 sites in Poland, 2 sites in
Italy, and 1 site each in Argentina, Serbia, and Russia) to
placebo or continued treatment with liprotamase. A total of 25
subjects from the safety population were not randomized for the
following reasons: baseline CFA N80% (n=14), occurrence of
an adverse event (n=4), protocol noncompliance (n=2),
withdrawal of consent (n=1), investigator decision (n=1),
and other reasons (n=3). Four subjects (2 randomized to
liprotamase, 2 randomized to placebo) withdrew after random-
ization due to the occurrence of an adverse event (n=3) or a
protocol deviation (CFA N80%, n=1).
Baseline characteristics for the 138 subjects who were
randomized to treatment with liprotamase or placebo are
detailed in Table 1. The age distribution was similar to that
seen in the 2008 annual data report from the CFF [24], but the
subjects in this study had lower baseline nutritional parameters
than the US CF registry population. In the ITT population, mean
baseline height, weight, and BMI Z-scores were −0.608,
−0.697, and −0.517, respectively; of note, subjects outside the
United States had considerably lower baseline height, weight,
and BMI Z-scores than those of US subjects. In general, the
treatment and control groups were well-matched for age,
gender, BMI, proportionate size of subgroup with CFA b40%,
and use of acid suppressants. However, mean and median FEV1
values were higher in the placebo group (77.8% and 82.5%,
respectively) than in the treatment group (70.2% and 72%,
respectively).
3.2. Efficacy
The adjusted mean change in CFA between baseline and
double-blind treatment was significantly greater in subjects
randomized to liprotamase than in those randomized to placebo
in the subgroup with baseline CFA b40% (n=44, 21.2% vs.
6.0%); the LSM difference (favoring the liprotamase vs.
placebo subjects) was 15.1% (p=0.001). In the subgroup with
Table 1
Baseline characteristics for 138 intent-to-treat (ITT) subjects randomized to liprotamase or placebo.
Baseline characteristics Liprotamase subjects (n=70) Placebo subjects (n=68) All ITT subjects (n=138)
Age (years)
Mean (SD) 18.5 (7.34) 17.7 (7.42) 18.1 (7.37)
Median (range) 18.0 (7–37) 16.0 (8–44) 17 (7–44)
7 to b12 years 13 (18.6%) 15 (22.1%) 28 (20.3%)
12 to b17 years 16 (22.9%) 20 (29.4%) 36 (26.1%)
≥17 years 41 (58.6%) 33 (48.5%) 74 (53.6%)
Male 45 (64.3%) 40 (58.8%) 85 (61.6%)
Caucasian 69 (98.6%) 65 (95.6%) 134 (97.1%)
US sites 36 (51.4%) 32 (47.1%) 68 (49.3%)
Sites outside US 34 (48.6%) 36 (52.9%) 70 (50.7%)
Weight Z-score a
Mean (SD) −0.736 (0.862) −0.658 (0.905) −0.697 (0.881)
Median (range) −0.749 (−2.776 to 1.090) −0.583 (−2.940 to 1.490) −0.673 (−2.940 to 1.490)
Height Z-score a
Mean (SD) −0.628 (0.998) −0.588 (0.992) −0.608 (0.991)
Median (range) −0.622 (−3.520 to 1.716) −0.541 (−2.967 to 1.321) −0.558 (−3.520 to 1.716)
BMI
Mean (SD) 19.1 (2.65) 19.2 (3.28) 19.1 (2.96)
Median (range) 19.4 (13.2 to 26.4) 19.4 (13.0 to 28.0) 19.4 (13.0 to 28.0)
BMI Z-score a
Mean (SD) −0.531 (0.832) −0.502 (1.015) −0.517 (0.924)
Median (range) −0.470 (−2.639–1.129) −0.442 (−2.962–1.979) −0.463 (−2.962 to 1.979)
BMI Z-score percentile a
b10th 11 (15.7%) 12 (17.6%) 23 (16.7%)
10th to b30th 21 (30.0%) 17 (25.0%) 38 (27.5%)
30th to b50th 18 (25.7%) 17 (25.0%) 35 (25.4%)
≥50th 20 (28.6%) 22 (32.4%) 42 (30.4%)
FEV1 % predicted
Mean (SD) 70.2 (25.15) 77.8 (24.79) 73.9 (25.17)
Median (range) 72.0 (21.0–119.0) 82.5 (29.0–137.0) 79.5 (21.0–137.0)
Baseline CFA
b40% 24 (34.3%) 20 (29.4%) 44 (31.9%)
≥40% but ≤80% 46 (65.7%) 48 (70.6%) 94 (68.1%)
On acid suppression 27 (38.6%) 26 (38.2%) 53 (38.4%)
SD: standard deviation; BMI: body mass index; CFA: coefficient of fat absorption; FEV1: forced expiratory volume in 1 second.
a Z-scores represent a measure of the normal population that is often used as a reference point (taking into account age and gender) when trying to assess the impact
of a therapy on height, weight, and BMI in a study population including subjects who are still growing.
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LSM difference was 8.6% (p=0.006), and in the overall ITT
population (n=138,13.8% vs 3.2%) the LSM difference was
10.6% (pb0.001) (Fig. 2, Table 2). In a post hoc analysis, for
alternative baseline CFA cutoff values for which comparison
between the treatment groups was possible, the LSM difference
in the adjusted mean change in CFA significantly favored
liprotamase over placebo (Fig. 3). The lower the baseline CFA,
the greater were the CFA differences.
Analysis of the effect of region on the LSM difference in the
adjusted mean change in CFA showed differences between
treatment sites in the United States and sites outside the United
States: a LSM difference of 16.6% (pb0.001) for all subjects at
the US sites (n=68) versus an LSM difference of 4.2% (p=NS)
for all subjects at the sites outside the United States (n=70)
(Fig. 2). Sample sizes were too small to allow comparisons
within individual countries, although most of the difference in
CFA between US sites and sites outside the United States was
driven by sites in a single high-enrolling country outside the
United States. A careful examination of the study methods andconduct did not reveal systematic errors to account for this
finding.
The use of acid suppressants was associated with an
enhanced treatment effect of liprotamase in subjects with low
baseline CFA (b40%). For this subgroup, the LSM difference
(favoring the liprotamase vs placebo subjects) in the adjusted
mean change in CFA was 26.6% (p=0.003) for those on acid
suppressants (overall n=18) compared to 9.6% (p=0.056) for
those not receiving acid suppressants (overall n=26). For the
overall population, the treatment effect of liprotamase compared
to placebo was similar in the group receiving acid suppression
therapy (overall n=53, LSM difference 12.6%, p=0.009) and
those not receiving this therapy (overall n=85, LSM difference
11.2%, pb0.001) (Fig. 2).
The unadjusted mean change in CNA between baseline and
double-blind treatment was significantly greater in subjects
randomized to liprotamase than in those randomized to placebo
in the subgroup with baseline CFA b40% (21.7% vs 9.0%), in
the subgroup with baseline CFA ≥40% but ≤80% (8.1% vs.
1.5%), and in the overall ITT population (13.3% vs. 4.1%)
Fig. 2. Mean change from baseline in coefficient of fat absorption (CFA) for CF subjects receiving liprotamase or placebo during the inpatient double-blind treatment
phase of the trial, with stratification for baseline CFA, in (A) the entire intent-to-treat (ITT) population, (B) subjects who were continued from baseline on acid
suppression versus subjects who did not receive acid suppression, and (C) subjects treated at US sites versus sites outside the United States.
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placebo subjects) in the adjusted mean change in CNA from
baseline to double-blind treatment was 12.7% (pb0.001) for the
subgroup with baseline CFA b40%, 6.6% (p=0.012) for the
subgroup with baseline CFA ≥40% but ≤80%, and 9.2%
(pb0.001) for the overall ITT population.
In a pre-specified analysis of the ITT nondiabetic population,
25.0% (13/52) of subjects randomized to liprotamase recorded
increases of ≥10 mg/dL in maximum blood glucose with the
SCT, compared with 32.7% (17/52) in the placebo group
(p=0.386).
The adjusted mean change in stool weight between baseline
and double-blind treatment was −334.7 g in the ITT liprota-mase group overall versus −117.7 g in the ITT placebo group
overall. A significant LSM difference of −217.0 g (p=0.0005)
was found between the liprotamase and placebo groups in terms
of change in stool weight.
The mean baseline stool frequency during the marker-to-
marker collection was 10.2 in the overall liprotamase group and
9.3 in the overall placebo group. The adjusted mean change
from baseline in stool frequency was −2.7 in the liprotamase
group versus −1.7 in the placebo group. The LSM difference
between the liprotamase and placebo groups in terms of change
in stool frequency was −1.0 per 72-hour stool collection
(p=0.0837). In either case, this stool frequency is clinically
acceptable.
Table 2
Change in coefficient of fat absorption (CFA) and coefficient of nitrogen absorption (CNA; in shaded boxes) by baseline CFA in the intent-to-treat (ITT) population.
Liprotamase subjects
(n = 70)
Placebo subjects
(n = 68)
LSM difference† (95% CI)
ANCOVA p value 
Baseline CFA < 40% (n)
LSM change in CFA* (SE)
24
21.2% (2.90%)
20
6.0% (3.21%)
15.1% (6.4% – 23.8%)
0.001
Baseline CFA ≥ 40% but ≤80% (n)
LSM change in CFA* (SE)
46
7.7% (2.23%)
48
– 0.9% (2.18%)
8.6% (2.5% – 14.7%)
0.006
Overall ITT population (n) 
LSM change in CFA* (SE)
70
13.8% (1.96%)
68
3.2% (1.97%)
10.6% (5.6% – 15.5%)
< 0.001
Baseline CFA < 40% (n)
LSM change in CNA* (SE)
24
21.7% (2.37%)
20
9.0% (2.60%)
12.7% (5.7% – 19.7%)
< 0.001
Baseline CFA ≥ 40% but ≤80% (n)
LSM change in CNA* (SE)
46
8.1% (1.83%)
48
1.5% (1.78%)
6.6% (1.5% – 11.7%)
0.012
Overall ITT population (n)
LSM change in CNA* (SE)
70
13.3% (1.60%)
68
4.1% (1.61%)
9.2% (5.0% – 13.4%)
< 0.001
ANCOVA: analysis of covariance; LSM: least squares mean.
*Analysis conducted using baseline observations carried forward method for subjects with no post-baseline data.
†Change in parameter (CFA/CNA) was analyzed using an ANCOVA model with fixed effects for treatment group and acid suppression usage with adjustment
for baseline CFA/CNA. Significant interactions with treatment group were included in the models.
††Change in parameter (CFA/CNA) was analyzed using an ANCOVA model with fixed effects for treatment group, CFA subgroup, and acid suppression usage
with adjustment for baseline CFA/CNA. Significant interactions with treatment group were included in the model.
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During the double-blind period, there were no trends or
clinically meaningful differences in adverse events between the
liprotamase and placebo groups. Overall, most of the adverse
events reported were gastrointestinal or pulmonary in nature
and were largely those expected for the underlying CF disease.
Eight subjects withdrew from the study because of adverseFig. 3. Adjusted mean change from baseline in coefficient of fat absorption (CFA) st
during the inpatient double-blind treatment phase of the trial. Values are least squarevents, 4 of those for abdominal pain or steatorrhea. Three of
these 4 withdrawals occurred prior to randomization. All 12
treatment-emergent serious adverse events reported in this study
were deemed to be either not related to the study drug or
unlikely to be related. There were 8 pulmonary exacerbations of
CF, 1 kidney-stone episode, and 1 pulmonary embolism. One
episode of DIOS occurred after 1 open-label-treatment day
following the baseline off-enzyme period. One episode ofratified by baseline CFA level for CF subjects receiving liprotamase or placebo
e means (LSM) plus standard error (SE).
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trampoline. No deaths were reported during the study.
There were no major safety concerns identified regarding
laboratory values. Abnormal alanine aminotransferase (ALT)
values with frequent fluctuations were seen. Nine subjects had
ALT levels ≥3 times the upper limit of normal while on study.
Five of these 9 subjects did not have normal ALT levels at
baseline. All elevations in ALT levels were transient,
asymptomatic, and not associated with increases in bilirubin,
and all 9 subjects completed the trial.
4. Discussion
This international study, the largest parallel-group, random-
ized, double-blind, placebo-controlled trial conducted to date in
EPI, demonstrated in an “all comer” CF patient population
reflective of that encountered in clinical practice that liprotamase
at a fixed dose of one capsule per meal or snack (5 capsules per
day) significantly increased fat and protein absorption as
measured by improvement in CFA and CNA and significantly
decreased stool weight. The capsule contents of 32,500 U
crystallized cross-linked lipase, 25,000 U crystallized protease,
and 3750 U amorphous amylase evaluated in this trial represented
themidrange andminimally effective dose from the phase II dose-
finding study of liprotamase [22]. This dose was found to bemore
effective than a dose fivefold lower and as effective as a dose
fourfold higher, based upon improvement in CFA and CNA and
reduction in stool weight [22]. CFA is an important short-term
measure of PERT efficacy, but as with other surrogate markers, it
cannot replace a clinically relevant outcome, which, in the case of
digestion, would be growth. Although the short-term improve-
ment in CFA achieved with liprotamase in this study, which did
not allow for dose increase, was less than what has been seen in
other studies comparing PERT to placebo, differences in design,
dose, run-in periods, inclusion and exclusion criteria, use of
concomitant medications, and methodology for CFA preclude
direct comparisons. Subjects in this study who were followed
over the course of 1 year showed stable growth on liprotamase.
Weight-based dosing recommendations for PERT were
formulated in the early 1990s in response to the epidemic of
fibrosing colonopathy, a potential complication when the
porcine PERT dosage was “titrated” (increased) on the basis
of symptoms with the thought that somehow this would
“optimize” the dose [2,12,25]. Although the cause of fibrosing
colonopathy is unknown, the enteric coatings [26], altered
colonic flora, dietary factors and factors related to bowel
motility, activation of fibrogenic cytokines, and the presence of
enzymes other than lipase have been implicated [2,12,25]. The
current maximum recommended dose of porcine-based PERT is
≤2500 USP U lipase per kg per feeding [2], ≤10,000 USP U
lipase per kg per day, or 4000 USP U lipase per gram of fat per
day [27]. These empiric recommendations were not based on
dose–response studies but rather were set at a level thought to
minimize the risk of fibrosing colonopathy. At the available
lipase unit strengths for the three currently FDA-approved
PERT products, a 50-kg patient taking the target lipase dose
studied in available porcine PERT trials could receive 5 or morecapsules per meal and snack (25 to 30 or more capsules per
day), amounting to 2 to 3 g of enteric coating, ~400,000 USP U
lipase, ~1,250,000 USP U protease, and ~2,000,000 USP U
amylase per day. In contrast, liprotamase contains no enteric
coating (removing the risk of phthalates) and delivers 162,500
USP U crystallized cross-linked lipase, 125,000 USP U
crystallized protease, and 18,750 USP U amorphous amylase
per day at the dose studied here. Our use of a dosing paradigm
with a fixed dose of liprotamase was driven partly by the
importance of conveying to patients and care providers that
dose should not be continuously titrated up.
Most PERT studies in which CFA is measured have selected
a dose intended to maximize fat absorption or included “dose
stabilization” or “normalization” periods during which doses are
adjusted purportedly to normalize malabsorption symptoms
[17–20]. In some studies, “nonresponders” have been excluded
based on the requirement that following dose “titration,” the on-
enzyme CFA must be ≥80% or subjects are not eligible for
randomization [17,20]. In contrast, our rigorously controlled
parallel-group, randomized-withdrawal trial was open to
nutritionally and functionally compromised patients, excluding
from randomization only those subjects whose baseline off
enzyme CFA was N80%, and the dosage of the study drug was
kept fixed. The range of CFA is quite wide in healthy
ambulatory CF subjects [28]. In the current trial, as in the
previous phase II dose-finding trial of liprotamase [22], the
CFA measurements during both the inpatient off-enzyme
baseline phase and the inpatient double-blind treatment phase
were lower than have been reported in recent trials of porcine-
based PERT [18,19]. As noted, substantial protocol design
differences make it impossible to compare CFA results across
trials. The subgroup stratification and primary efficacy analysis
in this phase III trial of liprotamase were based on a post hoc
analysis of data from our phase II study, which demonstrated
that subjects with baseline CFA ≤40% had a more profound
increase in CFA compared with subjects with baseline
CFA N40% (31% vs. 8%, pb0.0001) [22]. The finding of
subjects with the worst baseline fat and protein malabsorption
having the greatest improvements when treated had never
previously been reported, and was confirmed in the current trial
as well as in newer studies of porcine PERTs [18,19].
Some studies have excluded subjects on acid-suppressing
medications. In clinical practice, acid suppression therapy is
used because of the absence of bicarbonate secretion in EPI. In
some reports it has been associated with improved fat
absorption, postulated to be independent of digestion and
related to improved solubility of bile salts and enhanced micelle
formation and function [29,30]. We sought to study a broad-
based population, thus we stratified subjects according to
whether they were receiving daily acid suppression therapy at
baseline prior to randomization. Subjects in this study were
classified as on acid suppression therapy if they were taking a
proton pump inhibitor and/or an H2 blocker. For the overall
population, the treatment effect of liprotamase compared to
placebo was similar in the group receiving acid suppression
therapy (overall n=53, LSM difference 12.6%) and those not
receiving this therapy (overall n=85, LSM difference 11.2%).
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United States of America (USA) treatment sites versus those
outside the USA. Subjects enrolled outside the USA had lower
key baseline nutritional parameters than those in the USA and
much lower acid suppressant use (data not shown), suggesting
that there are substantial differences in patient management in
the USA versus the other countries. Differences in uncontrolled
ambulatory diet, overall health status, subject selection, experi-
ence in performing PERT studies, and underlying genetic
modifiers may also have contributed to outcome variations.
There was also variability in response by country, although
analysis is limited by small sample sizes. However, although there
were centers in six countries besides the United States
participating in the study, most of the difference in CFA between
USA sites and sites outside theUSAwas driven by sites in a single
high-enrolling country outside the USA. Because the study was
not stratified by region or country outside the USA, results for
some countries that differ from overall results may be a chance
finding due to small numbers of subjects in those countries.
No safety signals emerged during this study. We found
notable elevations of ALT in nine subjects, five of whom did
not have normal values at baseline. None met the Hy's Law
definition of hepatotoxicity [30], thus it is more likely that these
elevations were part of the underlying variation in trans-
aminases seen in patients with CF in research studies [31] rather
than as a direct result of liprotamase.
In summary, liprotamase significantly improved fat and
nitrogen absorption and reduced stool weight at a fixed dose of
one capsule (32,500 USP U lipase, 25,000 USP U protease, and
3750 USP U amylase) per meal or snack. No safety concerns
were identified. These efficacy and safety data support the use
of liprotamase for the treatment of EPI in patients with CF.
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